Overview
- The Lancet-led consensus announced in May formally renamed polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome (PMOS) to reflect evidence of whole-body endocrine and metabolic dysfunction.
- Reviews recommend retaining current adult diagnostic rules for now while validating objective biomarkers such as serum AMH, with one study flagging AMH >3.2 ng/mL for ages 23–35 as a potential ultrasound surrogate.
- PMOS is common and underdiagnosed, with prevalence estimates ranging from about 5% to 20% of reproductive-age people and research suggesting strong heritability with up to 60–70% daughter concordance in some analyses.
- Clinicians are calling for routine metabolic checks — fasting glucose, HbA1c, lipids and blood pressure — and for staged guideline, coding and education changes over the next roughly three years to enable earlier, individualized care.
- Treatment is shifting from symptom control to precision approaches: letrozole outperforms clomiphene for ovulation, GLP-1 drugs and NK3 antagonists show promise for metabolic and androgen features, and pregnancy-safety and broader validation remain urgent priorities.